Amwill Healthcare IPO

Amwill Health Care Ltd

₹1,26,000 /1200 sharesMinimum Investment

Amwill Healthcare IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
--₹111.00₹88.85-₹22.15 (19.95%)

Amwill Healthcare IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
5 Feb ‘25 - 7 Feb ‘25₹1,26,0001,200₹105 - ₹111
Issue SizeIPO Doc
59.98Cr
RHP PDF

Subscription rate

As of 07 Feb'25, 05:00 PM
Qualified Institutional Buyers7.80x
Non-Institutional Investor5.64x
Retail Individual Investor4.40x
Total5.29x

About Amwill Healthcare

Amwill Healthcare is a derma-cosmetic development company and is involved in the formulation of dermatological, cosmeceutical, and aesthetic products. By collaborating with contract manufacturers, distributors, and third-party development agencies, the company claims to have built on its manufacturing, packaging, and distribution capabilities. The company’s primary focus is on creating dermatological solutions, with all efforts directed toward product formulation and development. The company's product portfolio is categorised into two segments: Development and contract manufacturing of generic dermatological solutions and formulation of targeted solutions for specific dermatological concerns.;
Founded in
2017
Managing director
Mr. Anand Gandhi and Mr. Tarun Gandhi
Parent organisation
Amwill Health Care Ltd

Strengths & Financials of Amwill Healthcare

Strengths
Risks
The company offers a range of products addressing various dermatological issues, including hair care, skin care, and lip care. Its portfolio includes solutions for acne, ageing, fungal infections, allergies, excessive perspiration, skin lightening, specialised hair care, antioxidants, scar treatment, peri-orbital hyperpigmentation, vitiligo, and steroid and keratolytic treatments.
To maintain high-quality standards, the company claims to conduct thorough testing of its formulations through contract manufacturers. This ensures the final product meets the required molecular composition, texture, fragrance, and overall effectiveness. Additionally, prototypes are reviewed by dermatologists to verify their efficacy before launch.
The company has seen a consistent increase in revenue from operations. Revenue from operations increased from Rs 18.00 crore in FY22 to Rs 27.61 crore in FY23 to Rs 30.17 crore in FY24.

Amwill Healthcare Financials

*All values are in Rs. Cr
No Graph Data To Display

Application Details of Amwill Healthcare IPO

Apply asPrice bandApply upto
Regular105 - 111₹2 Lakh
High Networth Individual105 - 111₹2 - 5 Lakh
For Amwill Healthcare IPO, eligible investors can apply as Regular.
ⓒ 2016-2025 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.7.5
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW